MicroRNA-143-3p suppresses tumorigenesis by targeting catenin-δ1 in colorectal cancer

Xiaohua Ding¹
Jiying Du¹
Kai Mao²
Xiaoyu Wang¹
Yuange Ding¹
Fanping Wang¹†

¹School of Inspection and Imaging, Sanquan College of Xinxian Medical University, 453003, Henan, China; ²Department Two of Thoracic Diseases, Xinxian Central Hospital, 453003, Henan, China; ³School of Laboratory Medicine, Xinxian Medical University, 453003, Henan, China

Background: Colorectal cancer (CRC) is the third most common malignancy in the United States. Mounting microRNAs (miRNAs) have been identified as oncogenes or tumor suppressors in various cancers including CRC.

Materials and methods: The levels of microRNA-143-3p (miR-143-3p) and catenin-δ1 (CTNND1) were determined by RT-qPCR assay. Cell proliferative ability was assessed by Cell Counting Kit-8 assay. Cell migratory and invasive capacities were measured by transwell migration and invasion assay. Luciferase reporter assay was conducted to explore whether miR-143-3p could bind with CTNND1 3'UTR. CTNND1 protein level was determined through Western blot assay. Mouse xenograft models of CRC were established to test the functions and molecular basis of miR-143-3p in the development of CRC in vivo.

Results: Low amounts of miR-143-3p were expressed in CRC tissues and cells. Functional analysis revealed that miR-143-3p overexpression suppressed cell proliferation, migration and invasion in CRC. Molecular mechanism exploration indicated that miR-143-3p directly targeted CTNND1. Moreover, enforced expression of CTNND1 contributed to cell proliferation, migration and invasion in CRC, and CTNND1 silencing exerted opposite effects. Restoration experiments disclosed that CTNND1 upregulation weakened the inhibitory effects of miR-143-3p on CRC cell proliferation, migration and invasion. Additionally, miR-143-3p inhibited the growth of HCT116-derived xenograft tumors by targeting CTNND1 in vivo.

Conclusion: miR-143-3p hampered the development and progression of CRC by targeting CTNND1 in vitro and in vivo, deepening our understanding of the functions and molecular basis of miR-143-3p in the tumorigenesis of CRC and providing some candidate prognostic markers or therapeutic targets for CRC.

Keywords: microRNA-143-3p, CTNND1, colorectal cancer, tumorigenesis

Introduction
Colorectal cancer (CRC) is the third most common malignancy in the US, with an estimated 140,250 new cases and 50,630 deaths in 2018. With the advance of CRC management, the overall incidence and mortality of CRC was considerably reduced from 2000 through 2014 in the US. The 5-year survival rate is relatively higher (70%–90%) for patients with localized and regional CRC, while it declines to 13%–14% for patients with advanced CRC during the years of 2006–2012 in the United States. Thus, it is imperative to investigate the pathogenesis of CRC in order to identify more effective therapeutic targets or strategies.

MicroRNAs (miRNAs), a group of small RNA transcripts without protein-coding potential, participate in regulating various developmental and pathological processes by targeting protein-coding transcripts in animals including human. Over the past decades, mounting miRNA has been reported to be closely linked with tumor
initiation, development and metastasis in many malignancies including CRC. For instance, microRNA-382 (miR-382) suppressed cell proliferation, migration and invasion by targeting Krueppel-like factor 12 (KLF12) and homeodomain-interacting protein kinase 3 (HIPK3) in CRC. The depletion of microRNA-103 (miR-103) resulted in the reduction of cell proliferative, invasive and migratory capacities partly through targeting large tumor suppressor kinase 2 (LATS2) in CRC. MicroRNA-143-3p (miR-143-3p), located on chromosome 5q32, functioned as a tumor suppressor in some neoplasms such as triple-negative breast cancer, esophageal squamous cell cancer and ovarian cancer. Also, an earlier finding unveiled that miR-143-3p expression was reduced in CRC tissues relative to noncancerous colorectal tissues. Also, the Tumor Cancer Genome Atlas database (TCGA) analysis unveiled that miR-143-3p has lower expression in CRC patients with lymphovascular invasion relative to ones without lymphovascular invasion, hinting at the link between miR-143-3p and CRC tumorigenesis. However, the roles and molecular basis of miR-143-3p in the development of CRC need to be further explored.

In the literature, we found that miR-143-3p hampered proliferation, migration and invasion by reducing catenin-β1 (CTNND1) expression in CRC in vitro and in vivo, providing some potential therapeutic targets for CRC.

**Materials and methods**

**Clinical specimens and cell culture**

A total of 37 pairs of CRC tissues (Cancer) and matched adjacent non-cancer tissues (Normal) were obtained from patients with surgical resections at our hospital. All tissues were snap-frozen in liquid nitrogen and preserved at −80°C before utilization. Our project received the approval of the Ethics Committee of Sanquan College of Xinxiang Medical University, and the written informed consents from every patient and it was conducted in accordance with the Declaration of Helsinki.

Normal human colonic epithelial cell line NCM460 was acquired from INCCELL Corporation (San Antonio, TX, USA). CRC cell lines (HCT116 and SW620) were gained from American Type Culture Collection (ATCC, Manassas, VA, USA). HCT116 cells were cultured in McCoy’s 5a Medium (Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco). NCM460 and SW620 cells were maintained in DMEM medium (Gibco) supplemented with 10% FBS (Gibco). All cells were grown in a humidified atmosphere containing 5% CO₂ and 95% air at 37°C.

**Reagents and cell transfection**

Specific small interference RNA (siRNA) targeting CTNND1 (si-CTNND1), miR-143-3p mimic, miR-143-3p inhibitor and a scramble control (NC) were gained from GenePharma Co., Ltd (Shanghai, People’s Republic of China). CTNND1 coding region was subcloned into pcDNA3.1 vector (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) to get CTNND1 overexpression plasmid. All transfection was performed using Lipofectamine 2000 reagent (Invitrogen) referring to the instructions of manufacturer.

**RT-qPCR assay**

Total RNA was extracted from CRC tissues and cells using Trizol reagent (Invitrogen) following the manufacturer’s protocols. Next, 1 μg RNA was sequentially treated with 1 U RNase-free DNase I (Thermo Fisher Scientific) for 30 minutes at 37°C and 5 mM (final concentration) EDTA for 10 minutes at 65°C to remove DNA contamination. Then, cDNA first strand was synthesized from RNA using a Reverse Transcription (RT) System (Promega Corporation, Madison, WI, USA) and oligo(dT)15 primer (for CTNND1, β-actin or U6 snRNA) or specific RT primers (for miR-143-3p). Next, relative levels of miR-143-3p or CTNND1 were determined using SYBR Green PCR Master Mixes (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) and specific quantitative primers with U6 snRNA or β-actin as the internal control, respectively. The RT primer for miR-143-3p is 5′-GTGATATCCAGTGACGGGTCCGAGGATTCGCAGCACTGATACGACGAGCTA-3′.

Quantitative primers were displayed as follows: miR-143-3p, 5′-GTGAGATGAAGCAGTGCCTGACGCACGCCCTGATGGAAGC-3′ (forward) and 5′-GCGATGTGGTGTCGCTGACGAC-3′ (reverse); CTNND1, 5′-GTGATATCCAGTGACGGGTCCGAGGATTCGCAGCACTGATACGACGAGCTA-3′ (forward) and 5′-GCGATGTGGTGTCGCTGACGAC-3′ (reverse). U6, 5′-CTCGGCTTCGGCAGCAAATATTTGCGT-3′ (forward) and 5′-AACGCTTCAAAGAAATTTGCGT-3′ (reverse); CTNND1, 5′-GCGATGTGGTGTCGCTGACGAC-3′ (forward) and 5′-GCGATGTGGTGTCGCTGACGAC-3′ (reverse).

**Western blot assay**

At 48 hours after transfection, cells were lysed using ice-cold RIPA buffer (Beyotime Biotechnology, Shanghai, People’s Republic of China) containing protease inhibitor cocktail (Hoffman-La Roche Ltd, Basle, Switzerland) to extract proteins. Protein concentrations were determined using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Then, proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then
transferred onto polyvinylidene fluoride (PVDF) membranes. After blocking with 5% non-fat milk, the membranes were probed overnight at 4°C with anti-CTNND1 antibody (ab92514, 1:1,000, Abcam, Cambridge, UK) or anti-β-actin antibody (ab8227, 1:2,000, Abcam). Next, the blots were subsequently incubated for 1 hour at room temperature with Goat Anti-Rabbit IgG H&L (HRP) secondary antibody (ab6721, 1:2,000, Abcam). At last, chemoluminescent signals were visualized using Super Signal™ West Dura Extended Duration Substrate (Thermo Fisher Scientific) and quantified via Quantity One Software Version 4.1.1 (Bio-Rad Laboratories, Hercules, CA, USA).

Cell Counting Kit-8 (CCK-8) assay
Cell proliferative ability was examined using a Cell Counting Kit-8 kit (Beyotime Biotechnology) according to the manufacturer’s instructions. Generally, HCT116 and SW620 cells were plated into 96-well plates and then transfected with corresponding siRNAs, miRNAs or plasmids. At 48 hours after transfection, 10 µL of CCK-8 regent was mixed into each well of 96-well plates. After 1 hour of incubation, cell absorbance in each well was tested at a wavelength of 450 nm.

Luciferase reporter assay
Partial fragment of CTNND1 3’UTR with putative miR-143-3p binding sites was subcloned into psiCHECK-2 vector (Promega) to generate wild type CTNND1 reporter (WT). Also, mutant type CTNND1 reporter (MUT) with mutant miR-143-3p binding sites was produced using Fast Site-Directed Mutagenesis Kit (Tiangen Biotech Co., Ltd. Beijing, People’s Republic of China). Then, WT or MUT reporter was transfected into HCT116 and SW620 cells together with miR-143-3p mimic, miR-143-3p inhibitor or control NC. At 48 hours upon transfection, luciferase activities were determined using a dual luciferase reporter assay kit (Promega).

Transwell migration and invasion assay
Cell migratory or invasive capacity was examined using a transwell chamber containing 8 µm pores (Corning Incorporated, Corning, NY, USA) in the absence or presence of matrigel pre-coating (Corning Incorporated), respectively. At 24 hours after transfection, HCT116 and SW620 cells were collected and resuspended in serum-free medium. Then, transfected cells (5×10^4 cells/well for migration assay and 1×10^5 cells/well for invasion assay) were plated into the upper chamber, and medium supplemented with 20% FBS (Gibco) was put into the lower chamber. At 24 hours post incubation, cells on the upper surface of membranes were erased, and cells in the lower surface were fixed, stained, photographed and counted in 15 random fields.

Mice xenograft experiments
All experimental procedures got the approval of the Institutional Animal Care and Use Committee of Xinxiang Medical University. BALB/c mice (n=8, 6–8 weeks) were obtained from Shanghai Laboratory Animal Center of Chinese Academy of Sciences (Shanghai, People’s Republic of China) and bred following the national standard of the care and use of laboratory animals. For tumorigenesis experiments, HCT116 cells (5×10^6/100 µL) were subcutaneously inoculated into the right flanks of nude mice and this injection time was set as day 0. After 10 days, miR-143-3p mimic or a scramble control (NC) were injected into formed tumors every 5 days. Tumor volume was monitored every 10 days for a total of 50 days using a caliper. At the end of the experiments, the mice were sacrificed. Then, the tumors were excised, photographed and weighted. The CTNND1 level in tumors was also determined by RT-qPCR assay. The study was approved by the Institutional Animal Care and Use Committee of Sanquan College of Xinxian Medical University. All studies were conducted in accordance with the guidelines of the National Institutes of Health for the Care and Use of Laboratory Animals and approved by the Animal Care and Use Committee in Teaching and Research, Sanquan College of Xinxian Medical University.

Statistical analysis
All experiments were conducted at least in triplicate with the results showing as mean ± SD. Significance of difference between or among groups was computed by Student’s t-test or one-way ANOVA, respectively. Differences were considered as statistically significant when the P-value was below 0.05.

Results
MiR-143-3p expression was notably reduced in CRC tissues and cells, and was positively associated with better prognosis of CRC patients
Firstly, the expression pattern of miR-143-3p in CRC cells and tissues was examined by RT-qPCR assay. Results showed that miR-143-3p expression was remarkably reduced in CRC cell lines (HCT116 and SW620) as compared to that in normal human colon epithelial cell line NCM460 (Figure 1A). Also, miR-143-3p was lower expressed in CRC

Ding et al
OncoTargets and Therapy 2019:12 submit your manuscript | www.dovepress.com Dovepress 3257
tissues (n=37) compared with adjacent normal tissues (n=37) (Figure 1B). Moreover, CRC tissues (n=37) were divided into a high miR-143-3p expression group (n=18) and a low miR-143-3p expression group (n=19) by using the mean value of miR-143-3p in CRC tissues as a cut-off point. Following Kaplan–Meier survival analysis revealed that CRC patients with higher miR-143-3p expression have better prognosis, as evidenced by higher survival rate and longer survival time (Figure 1C). Generally, these data indicated that miR-143-3p might be implicated in CRC progression.

**MiR-143-3p overexpression inhibited cell proliferation, migration and invasion in CRC**

Following RT-qPCR assay confirmed that the transfection of miR-143-3p mimic resulted in the notable increase of miR-143-3p level in HTC116 and SW620 cells compared with control (Figure 2A). Next, CCK-8 assay unveiled that the enforced expression of miR-143-3p inhibited cell proliferation relative to negative control group in HTC116 and SW620 cells (Figure 2B). Also, increased miR-143-3p induced a notable reduction in migratory ability of HTC116 and SW620 cells (Figure 2C). Additionally, the invasive capacity of HTC116 and SW620 cells was decreased in response to the upregulation of miR-143-3p (Figure 2D). Taken together, these results revealed that miR-143-3p overexpression inhibited proliferation, migration and invasion of CRC cells.

**MiR-143-3p directly targeted CTNND1**

Then, miRNA target prediction website (TargetScan) was used to identify potential targets of miR-143-3p in humans. Among candidate targets, CTNND1 was previously reported to be a target of miR-145 in colon cancer14 (Figure 3A). It is well known that miR-145 is located in the same region with miR-143 in chromosome and clusters with miR-143.15 Hence, we supposed that miR-143-3p might exert anti-tumor effects by targeting CTNND1 in CRC. To further validate this conjecture, wild type CTNND1 reporter (WT) or mutant type CTNND1 reporter (MUT) containing wild or mutant miR-143-3p binding sites were constructed, respectively. Following luciferase reporter assay we found that the introduction of miR-143-3p mimic markedly reduced luciferase activity of wild type CTNND1 reporter (Figure 3B and C). Conversely, miR-143-3p inhibitor-induced miR-143-3p depletion cause a notable increase in luciferase activity of

---

**Figure 1** Expression of miR-143-3p was notably reduced in CRC tissues and cells, and was positively associated with better prognosis of CRC patients. **Notes:** (A) RT-qPCR assay was performed to detect expression of miR-143-3p in NCM460, HCT116 and SW620 cells. (B) Expression of miR-143-3p in 37 pairs of CRC tissues and adjacent normal tissues was measured by RT-qPCR assay. (C) Kaplan–Meier survival analysis for CRC patients based on the difference of miR-143-3p level. *P* < 0.05. **Abbreviation:** CRC, colorectal cancer.
wild type CTNND1 reporter in HTC116 and SW620 cells (Figure 3D and E). However, the introduction of miR-143-3p mimic (Figure 3B and C) or inhibitor (Figure 3D and E) had no much influence on luciferase activity of mutant type CTNND1 reporter in HTC116 and SW620 cells. In a word, these data disclosed that miR-143-3p could interact with CTNND1 3′UTR by putative binding sites. In support of these outcomes, we further demonstrated that CTNND1 protein level was obviously reduced in miR-143-3p-overexpressed HTC116 and SW620 cells, but was strikingly increased in miR-143-3p-depleted cells (Figure 3F). Additionally, CTNND1 level was inversely associated with miR-143-3p level in CRC tissues (Figure 3G). In summary, these results revealed that CTNND1 directly targeted CTNND1 in CRC cells.

CTNND1 overexpression contributed to CRC cell proliferation, migration, and invasion

Then, RT-qPCR assay further manifested that CTNND1 expression was strikingly upregulated in CRC tissues...
Figure 3 CTNND1 was a target of miR-143-3p.

Notes: (A) Predicted binding sites between miR-143-3p and CTNND1 3’ UTR and mutant sites in MUT. (B–E) hTc116 and sW620 cells were co-transfected with WT or MUT and miR-143-3p mimic, miR-143-3p inhibitor or the negative control, followed by the detection of relative luciferase activity at 48 hours after transfection with renilla luciferase activity as an endogenous control. (F) hTc116 and sW620 cells were transfected with miR-143-3p mimic, miR-143-3p inhibitor or the negative control. CTNND1 protein level was determined by western blot assay at 48 hours post transfection. (G) Correlation analysis between CTNND1 mRNA level and miR-143-3p expression in 37 cases of CRC tissues. *P<0.05.

Abbreviations: MUT, mutant type CTNND1 reporter; WT, wild type; NC, negative control; CRC, colorectal cancer.
(n=37) as compared to that in adjacent normal tissues (n=37) (Figure 4A). To further investigate the roles of CTNND1 in CRC progression, CTNND1 overexpression plasmid (CTNND1) or siRNA (CTNND1 siRNA) were transfected into HTC116 and SW620 cells. As displayed in Figure 4B and C, the introduction of CTNND1 overexpression plasmid resulted in a conspicuous upregulation of CTNND1 expression at mRNA (Figure 4B) and protein (Figure 4C)
levels in HTC116 and SW620 cells. Inversely, CTNND1 mRNA (Figure 4B) and protein (Figure 4C) expression was noticeably reduced in HTC116 and SW620 cells following the introduction of CTNND1 siRNA. In other words, these results showed that CTNND1 overexpression plasmid or siRNA could be used for subsequent functional experiments. As depicted in Figure 4D–F, cell proliferative, migratory and invasive abilities were all enhanced in HTC116 and SW620 cells following the upregulation of CTNND1 level, but was weakened in response to CTNND1 knockdown. That was to say, enforced expression of CTNND1 contributed to CRC cell proliferation, migration and invasion, while CTNND1 knockdown exhibited opposite effects.

CTNND1 upregulation alleviated miR-143-3p-mediated anti-proliferation, antimigration and anti-invasion effects in CRC cells

Next, Western blot assay manifested that CTNND1 overexpression notably abrogated miR-143-3p-mediated CTNND1 downregulation in HTC116 and SW620 cells (Figure 5A). Next, restoration experiments further demonstrated that upregulation of CTNND1 remarkably weakened the inhibitory effect of miR-143-3p on cell proliferation (Figure 5B), migration (Figure 5C) and invasion (Figure 5D) in HTC116 and SW620 cells.

MiR-143-3p inhibited the growth of HCT116-derived CRC xenograft tumors by targeting CTNND1

The data above prompted us to speculate that miR-143-3p might exert anti-tumor effect in CRC in vivo. To further confirm this conjecture, xenograft models of CRC were established by injecting HCT116 cells into the right flanks of nude mice. Then, the effect of miR-143-3p overexpression on the growth of CRC xenograft tumors was detected. As displayed in Figure 6A–C, ectopic expression of miR-143-3p resulted in a notable reduction of tumor weight (Figure 6B) and volume (Figure 6C) in vivo. Also, forced expression of miR-143-3p remarkably inhibited CTNND1 expression in

![Figure 5](image)

**Figure 5** CTNND1 upregulation alleviated miR-143-3p-mediated anti-proliferation, anti-migration and anti-invasion effects in CRC cells.

**Notes:** (A–D) HTC116 and SW620 cells were transfected with miR-143-3p alone or along with CTNND1 with untransfected cells as NC. At 48 hours after transfection, CTNND1 protein level (A), and cell proliferative (B), migratory (C) and invasive (D) abilities were determined by Western blot, CCK-8, transwell migration and invasion assay, respectively. *P<0.05.

**Abbreviations:** CRC, colorectal cancer; NC, negative control.
A B

NC miR-143-3p

Tumor weight (mg)

0 2 4 6 8

NC miR-143-3p

* *

C D

800 600 400 200 0

0 10 20 30 40 50

Days

Tumor volume (mm3)

40 50

01 02 03 0

NC miR-143-3p

* *

* CTNND1 mRNA expression

0.0 0.5 1.0 1.5

0

Figure 6 miR-143-3p inhibited the growth of HCT116-derived CRC xenograft tumors by targeting CTNND1.

Notes: HCT116 cells were subcutaneously inoculated into the right flanks of nude mice. After 10 days, miR-143-3p mimic or a scramble control were injected into formed tumors every 5 days for a total of 50 days. (A, B) At the end of the experiments, the tumors were resected, photographed (A) and weighed (B). (C) Tumor volume was monitored every 10 days for a total of 50 days. (D) CTNND1 mRNA level in tumors was determined by RT-qPCR assay at the end of the experiments. *P<0.05.

Abbreviations: CRC, colorectal cancer; NC, negative control.

CRC xenograft tumors (Figure 6D). In a word, these data indicated that miR-143-3p curbed CRC xenograft tumor growth through inhibiting CTNND1 expression in vivo.

Discussion

CRC is a major public health problem, bringing about massive economic burden for individuals and society worldwide.\textsuperscript{16,17} Recently, accumulating miRNA has been reported to be potential biomarkers or therapeutic targets for CRC prediction, diagnosis and treatment by virtue of their specific expression and central roles in the tumorigenesis of CRC.\textsuperscript{18,19} MiR-143 containing miR-143-3p and miR-143-5p has been reported to be downregulated in CRC cell lines and tissues.\textsuperscript{20–22} Moreover, prior studies showed that miR-143 suppressed CRC progression by regulating different targets.\textsuperscript{21,23,24} For example, miR-143 inhibited proliferation, migration and invasion through targeting metastasis-associated in colon cancer-1 (MACC1) in CRC cells (SW620 and SW480).\textsuperscript{21} However, a study pointed out that miR-143 overexpression inhibited cell invasion, but did not influence cell proliferation in CRC cell lines (HCT116 and SW480).\textsuperscript{25} In the present study, we further confirmed that miR-143-3p expression was notably reduced in CRC tissues and cell lines (HCT116 and SW620). Moreover, CRC patients with higher miR-143-3p expression had a better prognosis. Following functional analyses disclosed that miR-143-3p upregulation hampered proliferation, migration and invasion in HCT116 and SW620 cells.

Then, bioinformatical analysis, luciferase reporter assay and Western blot assay further evinced that miR-143-3p directly targeted CTNND1 in CRC cells. Also, CTNND1 level was inversely associated with miR-143-3p level in CRC tissues.

CTNND1, also named as p120-catenin, belongs to a protein subfamily with armadillo repeats (ARMs).\textsuperscript{26} Over the past decades, CTNND1 has been identified as a vital regulator of adherens junction maturation and stabilization.\textsuperscript{27,28} Moreover, CTNND1 can function as an oncogene or a tumor suppressor in cancers by regulating various signaling pathways such as MAPK, ROCK and Wnt pathway.\textsuperscript{28,29} For instance, CTNND1 upregulation promoted proliferation and metastasis of hepatocellular cancer cells partly through activating Wnt/β-catenin signaling in vitro and in vivo.\textsuperscript{30} However, Schackmann et al\textsuperscript{31} pointed out that CTNND1 deletion facilitated metastasis of breast cancer by activating growth factor receptor signaling and inducing anoikis resistance. Moreover, an earlier study pointed out that the downregulation of CTNND1 in CRC was linked with higher pathogenic status and unfavorable clinical outcome.\textsuperscript{32} Additionally, Greco et al\textsuperscript{33} pointed out that the knockdown of CTNND1...
resulted in a Co-029-dependent cell motility acceleration in colon cancer, hinting the anti-tumor effect of CTNND1 in colon cancer. However, Yamada et al.14 pointed out that CTNND1 knockdown inhibited proliferation, migration and invasion by disturbing nuclear translocation of β-catenin in DLD-1 and WiDr cells, while DLD-1 and WiDr cells are APC mutant CRC cell lines.34 Previous studies also showed that β-catenin was highly expressed in the cytoplasm and nucleus of HCT116 and DLD1 cells.35 Also, SW620 is a APC mutant CRC cell line, while the inactivation of APC can result in the constitutive activation of Wnt/β-catenin pathway.36–38 Hence, we supposed that miR-143-3p/CTNND1 might exert their function partly through regulating Wnt pathway in HCT116 and SW620 cells. However, the effect of miR-143-3p and CTNND1 on CRC cells that lack Wnt signaling needs to be further investigated. MiR-143-3p and CTNND1 might regulate these CRC cell developments by other signaling pathways.

Our study further showed that CTNND1 expression was notably increased in CRC tissues. Additionally, enforced expression of CTNND1 facilitated cell proliferation, migration and invasion in CRC. Conversely, the knockdown of CTNND1 resulted in the reduction of cell proliferative, migratory and invasive capacities in CRC.

Restoration experiments also manifested that CTNND1 upregulation reversed miR-143-3p-mediated anti-proliferation, anti-migration and anti-invasion effects in CRC cells. Also, mice experiments further demonstrated that miR-143-3p hamp ered CRC xenograft tumor growth by reducing CTNND1 expression in vivo.

Conclusion

In conclusion, our study manifested that miR-143-3p hindered the development of CRC via targeting CTNND1 in vitro and in vivo, providing a compelling argument for the significance of miR-143-3p and CTNND1 in the tumorigenesis of CRC and highlighting the potential values of miR-143-3p and CTNND1 in prediction, diagnosis, and treatment of CRC.

Acknowledgment

This study was granted by the Key scientific research projects in Henan Province (No 15A320009).

Author contributions

Xiaohua Ding, Jiyong Du, Kai Mao and Xiaoyu Wang performed the experiments. Xiaoyu Wang and Yuange Ding conceived and designed this work. Fanping Wang and Xiaohua Ding prepared the manuscript. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
2. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193.
3. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637–1649.
4. Gutting T, Burgermeister E, Härtel N, Ebert MP. Checkpoints and beyond – immunotherapy in colorectal cancer. Semin Cancer Biol. 2018.
5. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–524.
6. Shirafkan N, Mansoori B, Mohammadi A, Shomali N, Ghasbi M, Baradaran B. MicroRNAs as novel biomarkers for colorectal cancer: new outlooks. Biomed Pharmacother. 2018;97:1319–1330.
7. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer – a brief overview. Adv Biol Regul. 2015;57:1–9.
8. Yao H, Xia D, Li ZL, et al. MiR-382 functions as tumor suppressor and chemosensitizer in colorectal cancer. Biosci Rep. 2018:BSR20180441.
9. Zheng YB, Xiao K, Xiao GC, et al. MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2. Oncol Lett. 2016;12(3):2194–2200.
10. Li D, Hu J, Song H, et al. miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. Am J Transl Res. 2017;9(5):2276–2285.
11. He Z, Yi J, Liu X, et al. MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial-mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. Mol Cancer. 2016;15(1):51.
12. Shi H, Shen H, Xu J, Zhao S, Yao S, Jiang N. MiR-143-3p suppresses the progression of ovarian cancer. Am J Transl Res. 2018;10(3):866–874.
13. Chen X, Shi K, Wang Y, et al. Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. Oncotarget. 2015;6(35):37544–37556.
14. Yamada N, Noguchi S, Mori T, Naoe T, Maruo K, Akao Y. Tumor-suppressive microRNA-145 targets catenin δ-1 to regulate Wnt/β-catenin signaling in human colon cancer cells. Cancer Lett. 2013;335(2):332–342.
15. Kent OA, McCall MN, Cornish TC, Halushka MK. Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res. 2014;42(12):7528–7538.
16. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691.
17. Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi RE, Corcione F. Worldwide burden of colorectal cancer: a review. Updates Surg. 2016;68(1):7–11.
18. Masuda T, Hayashi N, Kuroda Y, Ito S, Eguchi H, Minohri K. MicroRNAs as biomarkers in colorectal cancer. Cancers. 2017;9(12):124.
19. Mohammadi A, Mansoori B, Baradaran B. The role of microRNAs in colorectal cancer. Biomed Pharmacother. 2016;84:705–713.
20. Pagliuca A, Valvo C, Fabrizi E, et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013; 32(40):4806–4813.
21. Zhang Y, Wang Z, Chen M, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 2012;11(1):23.
22. Kulda V, Pesta M, Topolcan O, et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet. 2010;200(2):154–160.
23. Akao Y, Nakagawa Y, Hirata I, et al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 2010;17(6):398–408.
24. Su J, Liang H, Yao W, et al. MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS One. 2014;9(12):e114420.
25. Bai JW, Xue HZ, Zhang C. Down-regulation of microRNA-143 is associated with colorectal cancer progression. Eur Rev Med Pharmacol Sci. 2016;20(22):4682–4687.
26. Keirsebilck A, Bonné S, Staes K, et al. Molecular cloning of the human p120ctn catenin gene (CTNND1): expression of multiple alternatively spliced isoforms. Genomics. 1998;50(2):129–146.
27. Reynolds AB. p120-catenin: past and present. Biochim Biophys Acta. 1773;2007(1):2–7.
28. Kourtidis A, Ngok SP, Anastasiadis PZ. p120 catenin: an essential regulator of cadherin stability, adhesion-induced signaling, and cancer progression. Prog Mol Biol Transl Sci. 2013;116:409–432.
29. Schackmann RC, Tenhagen M, van de Ven RA, Derksen PW. p120-catenin in cancer–mechanisms, models and opportunities for intervention. J Cell Sci. 2013;126( Pt 16):3515–3525.
30. Tang B, Tang F, Wang Z, et al. Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinosarcomas through activation of Wnt/β-catenin signaling. J Exp Clin Cancer Res. 2016;35(1):82.
31. Schackmann RC, Klarenbeek S, Vlug EJ, et al. Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling. Cancer Res. 2013;73(15):4937–4949.
32. Gold JS, Reynolds AB, Rimm DL. Loss of p120ctn in human colorectal cancer predicts metastasis and poor survival. Cancer Lett. 1998;132(1–2):193–201.
33. Greco C, Bralet MP, Ailane N, et al. E-cadherin/p120-catenin and tetraspanin Co-029 cooperate for cell motility control in human colon carcinoma. Cancer Res. 2010;70(19):7674–7683.
34. Kawasaki Y, Sato R, Akiyama T. Mutated APC and Asf are involved in the migration of colorectal tumour cells. Nat Cell Biol. 2003;5(3):211–215.
35. Tarapore RS, Siddiqui IA, Adhami VM, Spiegelman VS, Mukhtar H. The dietary terpene lupeol targets colorectal cancer cells with constitutively active Wnt/β-catenin signaling. Mol Nutr Food Res. 2013;57(11):1950–1958.
36. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–767.
37. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev. 1999;9(1):15–21.
38. Korinek V, Barker N, Morin PJ. Constitutive transcriptional activation by a-beta-Catenin-Tcf complex in APC–colon carcinoma. Science. 1997;275(5307):1784–1787.